Fresenius Kabi intros generic Folotyn
Generic Folotyn is used to treat adult patients with relapsed or refractory peripheral T-cell lymphoma.
Fresenius Kabi is offering pralatrexate injection, a generic to Acrotech Biopharma’s Folotyn.
The medication is used to treat adult patients with relapsed or refractory peripheral T-cell lymphoma.
[Read more: Fresenius Kabi debuts smaller-dose fentanyl citrate injection]
“Fresenius Kabi is committed to expanding access to high-quality, high-value oncology medicines,” said John Ducker, president and CEO of Fresenius Kabi USA. “We are pleased to offer pralatrexate in the United States and we intend to continue to bring new oncology medicines, including biosimilars, to U.S. patients.”
Fresenius Kabi’s generic Folotyn is available in two single-dose vial presentations — 20 mg/1 ml and 40 mg/2 ml.